# SGLT2 Adjunct in T1D

> **NCT07591077** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 86 (actual)

## Conditions studied

- Type 1 Diabetes
- Nephropathy, Diabetic

## Interventions

- **DRUG:** Empagliflozin (EMPA)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07591077
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-20
- **Primary completion:** 2025-11-20
- **Final completion:** 2026-02-20
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07591077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07591077, "SGLT2 Adjunct in T1D". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07591077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*